Page 257 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

10. DACARBAZINE ET TEMOZOLOMIDE 213

MARZOLINI C. et al., Pharmacokinetics of temozolomide in association with fotemustine
in malignant melanoma and malignant glioma patients : comparison of oral, intravei-
nous and hepatic intra-arterial administration, Cancer Chemother. Pharmacol., 1998,
42, 433-440.
BAKER, S.D. et al., Absorption, metabolism and excretion of 'C-temozolomide fol-
lowing oral administration to patients with advanced cancer, Clin. CancerRes., 1999,
5, 309-317.
BEALE P. et al., Effect of gastric pH on the relative oral bioavailability and pharmacoki-
netics of temozolomide, Cancer Chemother. Pharmacol., 1999, 44, 389-394.
BRADA M. et al., Phase I dose-escalation and pharmacocinetic study of temozolomide
(SCH 52365) for refractory or relapsing malignancies, Br. J. Cancer, 1999, 81, 1022-
1030.
CHOWDHURY S.K. et al., An LC/MS/MS method for the quantification on MTIC (5-(3-N-
methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product, in rat and
dog plasma, J. Pharm. Biomed. Anal., 1999, 19, 659-668.
HAMMOND LA. et al., Phase I and pharmacocinetic study of temozolomide on a daily-
for-5-days schedule in patients with advanced solid malignancies, J. Clin. Onco/ogy,
1999, 17, 2604-2613.
KIM H. et al., High-performance liquid chromatography analysis and stability of anti-
tupor agent temozolomide in human plasma, J. Pharm. Biomed. Anal., 2001, 24, 461-
468.

MÉCANISME D'ACTION
CLARK A.S. et al., Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozo-
lomide : probes for the major groove of DNA., Anti-cancer Drug Design, 1990, 5, 63-
68.
DENNY B.J. et al., NMR and molecular modeling investigation of the mechanism of acti-
vation of the antitumour drug temozolomide and its interaction with DNA, Biochemis-
try, 1994, 33, 9045-9051.
LEE S. M. et al., Inactivation of O-alkylguanine-DNA alkyltransferase in human periphe-
ral blood mononuclear cells by temozolomide, Br. J. Cancer, 1994, 69, 452-456.
CLARK A.S. et al., Antitumor imidazotetrazines. 32. synthesis of novel imidazotetrazino-
nes and related bicyclic heterocycles to probe the mode of action of the antitumor
drug temozolomide, J. Med. Chem., 1995, 38, 1493-1504.
GRIFFIN R.J. et al., The role of inhibitors of poly(ADP-ribose) polymerase as resistance-
modifiyng agents in cancer therapy, Biochimie, 1995, 77, 408-422.
TENTORI L. et al., Inhibition of O-alkylguanine DNA-alkyltransferase or poly(ADP-
ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by
temozolomide, Molec. Pharmacol., 1997, 52, 249-258.
ARROWSMITH J. et al., Antitumour lmidazotetrazines. Part 37. Conjugation of the DNA
major-groove alkylating imidazotetrazine mitozolomide to peptide motifs recognizing
the minor groove, Anti-cancer Drug Design, 1999, 14, 205-217.
6
MIDDLETON M.R et al., 0 -(4-bromothenyl)guanine improves the therapeutic index of
temozolomlde against A375M melanoma xenografts, /nt. J. Cancer, 85, 248-252.
HIROSE Y. et al., p53 affects duration of G,-M arrest and the fate of temozolomide-
treated human glioblastoma cells, Cancer Res., 2001, 61, 1957-1963.